Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To evaluate the safety，tolerability，pharmacokinetic characteristics and preliminary efficacy of HR19024 injection in the treatment of advanced solid tumor
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| HR19024 | Experimental | Part 1: Dose escalation of HR19024 montherapy for advanced solid tumor Part 2：PK expansion of HR19024 montherapy for advanced solid tumor Part 3: Efficacy expansion of HR19024 montherapy for advanced solid tumor |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| HR19024 | Drug | Intravenous infusion |
|
| Measure | Description | Time Frame |
|---|---|---|
| Maximum tolerated dose (MTD) of HR19024 | 21-day cycle (tri-weekly) |
| Measure | Description | Time Frame |
|---|---|---|
| Response rate (RR) | up to 6 months following the date the last patient was randomized | |
| Disease Control Rate | up to 6 months following the date the last patient was randomized | |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Fudan University Shanghai Cancer Center | Shanghai | Shanghai Municipality | 200032 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
HR19024 for all enrolled subjects
Not provided
Not provided
Not provided
Not provided
| Duration of Response |
| up to 6 months following the date the last patient was randomized |
| Progression free survival (PFS) | up to 6 months following the date the last patient was randomized |